StockData
Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc. (RANI) stock

RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3043% above fair value
$0.65+0.09 (+15.86%)

Close on Nov 18, 2026Market cap $90.34MP/E –Yield –

Rani Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Rani Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $4.88M, up 306.4% year over year. For fiscal 2025 it was $1.63M, up 58.9% from the year before. The highest annual figure on record is $2.72M in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.63M+58.9%
FY2024Dec 31, 2024$1.03M–
FY2023Dec 31, 2023$0–
FY2022Dec 31, 2022$0-100.0%
FY2021Dec 31, 2021$2.72M+488.1%
FY2020Dec 31, 2020$462.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.71M–
Q1 FY2026Mar 31, 2026$1.71M+893.0%
Q4 FY2025Dec 31, 2025$1.46M+42.1%
Q3 FY2025Sep 30, 2025$0–
Q2 FY2025Jun 30, 2025$0–
Q1 FY2025Mar 31, 2025$172.00K–
Q4 FY2024Dec 31, 2024$1.03M–
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$0–
Q1 FY2024Mar 31, 2024$0–
Q4 FY2022Dec 31, 2022$0–
Q3 FY2022Sep 30, 2022$0-100.0%
Q2 FY2022Jun 30, 2022$0-100.0%
Q4 FY2021Dec 31, 2021$0-100.0%
Q3 FY2021Sep 30, 2021$0-100.0%
Q2 FY2021Jun 30, 2021$1.96M+3168.3%
Q1 FY2021Mar 31, 2021$756.00K–
Q4 FY2020Dec 31, 2020$210.00K–
Q3 FY2020Sep 30, 2020$108.00K–
Q2 FY2020Jun 30, 2020$60.00K–

More Rani Therapeutics figures

See a number that looks wrong?